NCT06945419
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Completed
PHASE1Ages 18–65InterventionalBasic scienceEli Lilly and Company
~219 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:LY4086940Placebo
At a glance
Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Measured over Baseline up to Week 9
Conditions
Where it's being run
5 sites across 3 statesFlorida2
Texas2
Singapore1
Study leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Have no significant body weight change for the 3 months prior to screening
Are considered healthy
Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
Have a BMI of 27 to 45 kg/m2 at screening
Have a BMI of 25 to 45 kg/m2 at screening
Have type 2 diabetes
Have hemoglobin A1C (HbA1c) ≥6.5% and ≤10.5% at screening
Have a BMI of 27 to 45 kg/m2 at screening
Exclusion
Have had an acute cardiovascular condition within the past 6 months prior to screening
Have liver disease or pancreatitis
Have used medications for weight loss within the 3 months prior to screening
Have any form of diabetes
Have type 1 diabetes
What this trial measures
- Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug AdministrationBaseline up to Week 9